+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Rheumatoid Arthritis Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4592783
  • Report
  • June 2022
  • Region: Global
  • 118 Pages
  • Mordor Intelligence


  • AbbVie Inc.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co. Inc.
The Rheumatoid Arthritis Drugs Market is poised to grow at a CAGR of 5.6% during the forecast period (2022-2027).

COVID-19 has significantly impacted the rhematoid arthritis (RA) as RA has higher risk of COVID-19 infection. For instance, according to the study published in Arthritis & Rheumatology, titled 'Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals' in October 2021, patients with Rheumatoid Arthritis (RA) are more likely than those without RA to develop COVID-19 and severe COVID-19 (which can lead to hospitalization or death). In addition, according to the study published in Future Virology, titled 'The COVID-19 pandemic: an increased risk of rheumatoid arthritis' in June 2021, Because of the iatrogenic consequences of RA-related pharmacological therapy, patients predisposed to RA have a greater infection risk than the general population. As a result, a COVID-19 pandemic might increase the probability of a health emergency in complicated conditions like RA. Such studies shows that the COVID-19 infection has significantly impacted the rheumatoid arthritis market over the forecast period.

The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals, among others.

According to the study published in Rheumatology International, titled 'The global prevalence of rheumatoid arthritis (RA): a meta-analysis based on a systematic review' in November 2020, the global prevalence of RA was estimated to be 0.46 percent. This will lead to increased adoption of therapies for RA, driving the market growth.

There are also several therapeutics and medications that have been developed in the recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid arthritis drugs management is generally associated with a high cost. Most commonly used drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. The biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines. However the costs of rheumatoid arthritis drugs and NSAIDs are less than biologics. Thus, growing availability and awareness of safer drugs are anticipated to increase the global rheumatoid arthritis drugs market.

Rising product launches by the market players is expected to drive the growth of this market further. For instance, in September 2020, Lupin has launched generic leflunomide in the United States for the treatment of adults with active rheumatoid arthritis (RA). This will lead to increased adoption of rheumatoid therapies in patients, driving the market growth.

Moreover, rising approvals of biosimilars for the treatment of rhematoid arthritis is expected to drive the market growth furhter due to increased adoption of biosimilars. For instance, in October 2021, the United States Food and Drug Administration has approved Cyltezo, the first interchangeable biosimilar to Humira for the treatment of rheumatoid arthritis.

Hovever, alternative treatment options, and patent expiration of branded drugs is expected to hinder the market growth durign the forecast period.

Key Market Trends

NSAIDs Segment is Expected to Show Major Share Over the Forecast Period

NSAIDs segment is expected to hold a major share in the rheumatoid arthritis drugs during the forecast period.

NSAIDs are being widely utilized for the symptomatic treatment of rheumatic disorders. Disease-modifying anti-rheumatic drugs (DMARDs) are also considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Unlike conventional DMARDs, the NSAIDs give symptomatic relief, biologic drugs are more efficient in the management of rheumatoid arthritis.

The increasing prevalence of the disease globally is boosting the segment growth. With the growing number of arthritis cases, the use of NSAIDs and their production is expected to observe healthy demand and supply throughout the forecast period.

According to the study published in Frontiers in Immunology, titled 'Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis' in July 2021, nonsteroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylate, naproxen, ibuprofen, and etodolac, are used to alleviate pain, swelling, and decrease inflammation and are used as the first line treatment for rheumatoid arthritis. This has led to increased adoption of NSAIDs in the therapy of this disease, driving this segment growth.

In addition, rising launch of NSAIDs for the treatment of rheumatoid arthritis is further expected to drive the growth of the segment studied. For instance, in August 2021, Alkem Laboratories has launched Ibuprofen and Famotidine tablets, used to relieve the symptoms of rheumatoid arthritis and osteoarthritis, in the United States. Furthermore, in September 2021, Lupin has launched generic Duexis (ibuprofen and famotidine) tablets used to treat the symptoms of rheumatoid arthritis and osteoarthritis in the United States market.

This shows a steady growth in arthritic cases, supporting the expected growth of NSAIDs in the market.

North America Holds a Significant Share and is Expected to Follow the Same Trend Over the Forecast Period

North America is expected to hold a major share in the rheumatoid arthritis market and is expected to show the same trend over the forecast period.

Factors such as rising prevalence of disease, strong foothold of key market players, rising launch of novel therapies such as monoclonal antibodies for rheumatoid arthritis, rising investments from the market players on the research for the development of novel therapies and biosimilars for this disease, among others are expected to drive the market growth in this region.

According to the Center for Disease Control and Prevention (CDC) updated in October 2021, about 1 in 4 United States adults (23.7%) or about 58.5 million people have doctor-diagnosed arthritis. Futhermore, According to the Government of Canada in September 2020, approximately 374,000 (1.2%) Canadians aged 16 years and older live with diagnosed rheumatoid arthritis. Such a huge prevalence of this disease will lead to increased adoption of therapies for this, driving the market growth.

In addition, in May 2020, Teva and Celltrion Healthcare has launched TRUXIMA (rituximab-abbs) Injection for Rheumatoid Arthritis, the biosimilar of Rituxan(rituximab) for this indication in the United States. Moreover, the United States Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults (18 years and older). This will further lead to increased adotpion of rheumatoid arthritis therapies in the United States, driving the market growth over the forecast period.

Therefore, owing to the above mentioned factors, the growth of rheumatoid arthritis market in North America is expected to drive over the forecast period.

Competitive Landscape

The market for rheumatoid arthritis is moderately competitive and a majority of rheumatoid arthritis drug products are being manufactured by key players. The market leaders in this industry have established their position in the market, and these manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in the Asia-Pacific region are witnessing the entry of small players. Some of the major players in this market include AbbVie Inc., Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli lilly and Company, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • AbbVie Inc.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co. Inc.

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Preference Towards Development of Biologics and Biosimilars
4.2.2 Rising Burden of Arthritis
4.3 Market Restraints
4.3.1 Patent Expiration of Blockbuster Drugs
4.3.2 Alternative Treatment Options
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Type of Molecule
5.1.1 Pharmaceuticals
5.1.2 Biopharmaceuticals
5.2 By Drug Class
5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.2 Corticosteroids
5.2.3 Analgesics
5.2.4 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over-the-counter (OTC)
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East & Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 Bayer AG
6.1.4 Boehringer Ingelheim GmbH
6.1.5 Bristol-Myers Squibb Company
6.1.6 Celgene Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Johnson & Johnson
6.1.9 Merck & Co. Inc.
6.1.10 Novartis AG
6.1.11 Lupin Limited
6.1.12 Alkem Laboratories
6.1.13 Regeneron Pharmaceuticals
6.1.14 Eli Lilly and Company
6.1.15 Pfizer Inc
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc.Amgen Inc.
    Bayer AG
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Celgene Corporation
    F. Hoffmann-La Roche AG
    Johnson & Johnson
    Merck & Co. Inc.
    Novartis AG
    Lupin Limited
    Alkem Laboratories
    Regeneron Pharmaceuticals
    Eli Lilly and Company
    Pfizer Inc
Note: Product cover images may vary from those shown